Placo announced that the company recently received clinical trial approval for the African swine fever subunit vaccine issued by the Ministry of Agriculture and Rural Affairs. The approval number is 2026047. The validity period is from September 29, 2026 to September 28, 2028, and it has agreed to conduct clinical trials at approved test sites. The vaccine is used to prevent infection with the African swine fever virus. Since 2019, the company has cooperated with research institutes to develop it. Up to now, it has invested about 92 million yuan in research and development. The product will need to complete clinical trials, submit a registration application, and obtain a relevant certificate number before it can be marketed. There are uncertain risks such as research and development failure and progress falling short of expectations.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.